Peg-IFN-alfa2a/Ribavirin combination therapy for chronic hepatitis C with serogroup1 and high viral load: analysis of IL28B gene and efficacy of vitamin D combination

Peg-IFN-alfa2a/Ribavirin combination therapy for chronic hepatitis C with serogroup1 and high viral load: analysis of IL28B gene and efficacy of vitamin D combination - Peg-IFN-alfa2a/Ribavirin combination therapy with/without vitamin D for chronic hepatitis C with serogroup1 and high viral load

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008197

Enrollment

200

Registered

2012-06-19

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

IL-28B Gene major: Peg-IFN-alfa2a/Ribavirin IL-28B Gene major: Peg-IFN-alfa2a/Ribavirin/VitaminD IL-28B Gene minor: Peg-IFN-alfa2a/Ribavirin/VitaminD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C serogroup1 and high viral load

Exclusion criteria

Exclusion criteria: contraindication of Peg-IFN/Ribavirin therapy

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactTetsuro Shimakami

Kanazawa university University hospital

shimakami@m-kanazawa.jp076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026